home
Author : adminDate : 2020-09-24 12:30

HLB receives IND approval from MFDS for global clinical trial for colon cancer treatment

- Accelerated development by approval of MFDS's third-line treatment for colorectal cancer phase 1b/2 clinical trial

 

Elevar Therapeutics announced that they received an Investment New Drug (IND) approval from the Korean Registry of Food and Drug Safety (MFDS) for phase 1b/2 of clinical trials of combination therapy with Rivoceranib and Lonsurf (Taiho Pharmaceutical, Japan) for the development of a third-line treatment for colorectal cancer.  

 

As appropriate dosage determination was completed in the ongoing global clinical trials of Rivoceranib and Lonsurf, clinical trials were also approved in Korea to prepare for the second phase. The safety and drug resistance are evaluated to determine the dose without side effects on the patient through Phase I and the treatment effect is confirmed with the dose determined in Phase II clinical trials.

 

This clinical trial will be conducted at Washington University School of Medicine, Vanderbilt University, and Florida Cancer Specialists, along with Asan Medical Center, Samsung Medical Center, Seoul National University Bundang Hospital, Seoul National University Hospital, and Severence Hospital in Korea.

 

The combined therapy of Rivoceranib and Lonsurf can effectively block recurrence and metastasis by Lonsurf acting directly on cancer cells to induce apoptosis, and Rivoceranib inhibiting the production of neoplasms needed for tumor growth, normalizing abnormal cancer vascular structures and activating immune cells. In addition, Rivoceranib and Lonsurf are expected to be the best combination because they do not overlap with side effects and are both easy to take as oral medicines.

 

An official from HLB said, " In addition to the U.S., IND will be approved in Korea and the recruitment of patients will be accelerated," adding, "We will do our best to give hope to patients with terminal colorectal cancer through rapid clinical progress through global collaboration."